A study by Yang et al. used dopamine transporter (DAT) imaging to assess dopaminergic neuron integrity in PD patients before and after COVID-19 infection and observed accelerated loss of dopaminergic signal in those who had recovered from COVID-19.66 This finding suggests that SARS-CoV-2 infection may directly affect these vulnerable neurons, potentially explaining the more rapid progression of motor symptoms observed in some PD patients following COVID-19. This evidence concerns the gene SLC6A3 and COVID-19.